NCT05839106View on ClinicalTrials.gov

Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

April 10, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Tumor
Interventions
DRUG

PM1032 injection

Subjects will receive PM1032 by intravenous administration.

Trial Locations (3)

Unknown

RECRUITING

Shulan (Hang Zhou) Hospital, Hangzhou

RECRUITING

The first affiliated hospital of nanchang university, Nanchang

RECRUITING

Shanghai Orient Hospital, Shanghai

Sponsors

Lead Sponsor

Biotheus Inc.
All Listed Sponsors
lead

Biotheus Inc.

INDUSTRY